Background Our institution established in October 2013, in collaboration between the pharmacy unit, haematology laboratory, clinicians and according with recommendations of the GIHP, a prefilled prescription form (PPF) for Kanokad^® (Prothrombin Complex Concentrate) and Feiba® (activated Prothrombin Complex Concentrate) used in the indication of antagonising DOAs. The PPF has the form of a flow chart and indicates to the prescriber which product and dose to prescribe according to the clinical situation. The PPF was validated by the Hospital Drug Committee.

Purpose The objective of this study is to realise an inventory of good prescribing practices of Kanokad® and Feiba® relative to the established protocol.

Material and methods A retrospective study over 12 months (October 2013–September 2014) was performed with analysis of the prescriptions of Kanokad® and Feiba®. The conformity of the prescriptions was determined based on the choice of the product and the respect of the recommended dosage.

Results 16 patients were treated in the indication of antagonising DOAs. 8 patients received Kanokad®, 7 Feiba® and 1 Feiba® followed by Kanokad®. DOAs concerned was Rivaroxaban (63%) and Dabigatran (31%) (unknown for 1 patient). Indications were: treatment of severe bleeding (76%) and prevention of bleeding during surgery (18%) (unknown for 1 patient). The choice of the medicine and dosage was in consistent with the protocol for 87.5% of patients. For 12.5% of the prescriptions, the prescribed dosages were lower than recommended, and we could not check-up the choice of the product (PPF incomplete). They concerned a unit which has an emergency reserve stock of Kanokad® (pharmaceutical validation performed retrospectively).

Conclusion The PPF is generally well applied. Measures were implemented for the 12.5% non-compliant prescriptions: prescribers were contacted and the PPF was sent them by E-mail. Furthermore, the PPF will now be joined to the Kanokad® bottles at each renewal of the emergency reserve stock.

References and/or acknowledgements none

No conflict of interest.